Clinical trial · Observational
Application of MRI in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer
Application of MRI Quantitative Parameters in Identifying Myelosuppression Risk of Neoadjuvant Chemoradiotherapy for Rectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Rectal cancer patients who received neoadjuvant chemoradiotherapy in Peking University Third Hospital in 2021 are divided into acute myelosuppression group, chronic myelosuppression group and normal group. The differences of magnetic resonance parameters between the groups were compared. The risk identification model of acute and chronic myelosuppression after neoadjuvant chemoradiotherapy was established by clinical risk factors and quantitative parameters of magnetic resonance imaging, and the prediction efficiency of the model was evaluated.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rectal Cancer Stage II | Malignant Rectal Neoplasm | CURATED_BROADER | 0.78 |
| Rectal Cancer Stage III | Malignant Rectal Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood routine test | Diagnostic Test | — | UNRESOLVED |
| MRI | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- acute myelosuppression group
- description
- WBC \<4.0×10\^9 14 days after radiotherapy
- interventionNames
- Diagnostic Test: MRI
- Diagnostic Test: blood routine test
- label
- chronic myelosuppression group
- description
- WBC \<4.0×10\^9 90 days after radiotherapy
- interventionNames
- Diagnostic Test: MRI
- Diagnostic Test: blood routine test
- label
- no myelosuppression group
- description
- WBC \>4.0×10\^9 during radiotherapy
- interventionNames
- Diagnostic Test: MRI
- Diagnostic Test: blood routine test
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * From February 2021 to August 2022, patients with locally advanced rectal cancer were treated with neoadjuvant chemoradiotherapy in the Third Hospital of Peking University. * There were blood routine before radiotherapy, 1 week, 2 weeks and 90 days after radiotherapy, and MRI examination including routine MRI sequence and IDEAL-IQ sequence before radiotherapy, 1-2 weeks and 90 days after radiotherapy. * Each patient used the same chemotherapy regimen. Exclusion Criteria: * Patients with metabolic bone diseases such as hyperparathyroidism and Cushing's syndrome. * Patients with history of pelvic radiotherapy or systemic chemotherapy. * Patients with leukocytes below 4.0×10\^9/L or long-term severe anemia before radiotherapy. * Patients with tumor bone metastases; patients with pelvic trauma, fracture, and infectious diseases.
References
Publications (0)
Data not yet available